跳至主要内容
临床试验/NCT06565338
NCT06565338已完成不适用

Comparison Between the Neuroprotective Effect of Vitamin D Versus Dexmedetomidine in Patients with Traumatic Brain Injury Using Interleukin 6 As Inflammatory Marker

Minia University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年4月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
The primary endpoint aims to measure the inflammatory markers level:

研究概览

简要总结

in this study the investigators compare between the neuroprotective effect of vitamin d versus dexmedetomidine in patients with traumatic brain injury using interleukin 6 as inflammatory biomarker

详细描述

patients with moderate head trauma (GCS 8-12) within first 24 hours were randomly divided into 2 groups, first group received 100,000 IU of vitamin D was given IM & the other group received dexmedetomidine 0.4 mic/kg as loading dose then 0.25 mic/kg/hr as maintainence dose for 5 days detecting APATCHE at admission and following up of vital signs (HR & NIBP) & investigations (CBC & RFT& ABG & ESR& CRP & IL-6) & GCS and GOS for 5 days.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Both Gender.
  • Age (18-50)
  • GCS (8-12)
  • Pt with traumatic brain insult who not indicated surgical intervention

排除标准

  • Prior severe disability.
  • Isolated brain system lesions.
  • History of underlying neurologic, metabolic or psychiatric disorders.
  • Alcohol or drug abuse.
  • Pregnancy.
  • Patients with intracranial hemorrhage who indicated surgical evacuation.
  • Multisystem life-threatening trauma.
  • GCS > 12 & <
  • Vitamin d deficiency.

研究组 & 干预措施

group A

dexmedetomidine 0.4 mic/kg loading dose then 0.25 mic/kg/hr for 5 days

干预措施: Dexmedetomidine (Drug)

group B

vitamin D 100.000 IU given IM once

干预措施: Vitamin D3 (Drug)

结局指标

主要结局

The primary endpoint aims to measure the inflammatory markers level:

时间窗: 5 days

1- IL-6 in the unit of (pg/mL).

Primary outcome measure

时间窗: 5 days

3- CRP in the unit of (mg/L).

次要结局

  • The secondary endpoints aim to compare ICU stay, morbidity and mortality in both groups:(3 months)
  • Secondary outcome measure(3 month)

研究者

发起方
Minia University
申办方类型
Other
责任方
Principal Investigator
主要研究者

asmaa elhelw

Investigator

Minia University

研究点 (1)

Loading locations...

相似试验